Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Webcasts


Play
Remnant lipoproteins and impact of PCSK9 inhibition
Play
Genome-wide polygenic risk scores: Insights from ODYSSEY OUTCOMES
Play
Genetic risk scores: How much do they add?
Play
What’s new in very high-risk patients?
Play
Do the new ESC/EAS guidelines change your clinical practice? Acute coronary syndromes
Play
ODYSSEY OUTCOMES and stroke events
Play
Treat ischaemic stroke to target
Play
Endothelial LDL transcytosis in atherosclerosis
Play
Emerging lipid science: ApoE and chronic disease
Play
ODYSSEY OUTCOMES: Update
Play
New data from FOURIER and design of the VESALIUS-CV Trial
Play
PCSK9 Genetics: New Insights
Play Hepatic lipid metabolism: Storage vs secretion
Jan Boren Hepatic lipid metabolism: Storage vs secretion
Play Using naturally randomized genetic evidence to estimate the clinical benefit of lowering triglyceride-rich lipoproteins
Using naturally randomized genetic evidence to estimate the clinical benefit of lowering triglyceride-rich lipoproteins
Play New approaches to treatment of moderate hypertriglyceridemia and new therapeutic combinations
Erik Stroes New approaches to treatment of moderate hypertriglyceridemia and new therapeutic combinations
Play Inclisiran: The Phase 3 trial
Frederick J. Raal Inclisiran: The Phase 3 trial
Play FOURIER trial: Update on subgroup analyses
Peter Sever FOURIER trial: Update on subgroup analyses
Play ODYSSEY OUTCOMES: Update
Andreas M Zeiher ODYSSEY OUTCOMES: Update
Play The new AHA/ACC Treatment Guidelines: Critical appraisal
Henry Ginsberg The new AHA/ACC Treatment Guidelines: Critical appraisal
Play Is it time to upgrade Lp(a) to a therapeutic target in Guidelines?
Børge Nordestgaard Is it time to upgrade Lp(a) to a therapeutic target in Guidelines?